Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00832234 | Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia(BDR-WM) | completed | Phase 2 | 59 | European Myeloma Network B.V.NETWORK | 1 | Feb 18, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 |
| clinicaltrials |
| NCT01849848 | Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 17 | SymBio PharmaceuticalsINDUSTRY | 1 | Feb 6, 2015 | clinicaltrials |
| NCT00073931 | Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 25 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 5, 2015 | clinicaltrials |
| NCT01310101 | Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 33 | Brno University HospitalOTHER | 1 | Feb 3, 2015 | clinicaltrials |
| NCT00440583 | The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP | completed | Phase 2 | 15 | Mahidol UniversityOTHER | 1 | Jan 30, 2015 | clinicaltrials |
| NCT00560794 | Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 21 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00908232 | Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD(SEQUENTIAL) | completed | Phase 2 | 163 | Janssen-Cilag International NVINDUSTRY | 10 | Jan 15, 2015 | clinicaltrials |
| NCT00002592 | Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 14, 2015 | clinicaltrials |
| NCT00435916 | Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 46 | Seagen Inc.INDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT00528333 | A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML | completed | Phase 2 | 211 | Seagen Inc.INDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT00381550 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2015 | clinicaltrials |
| NCT00193492 | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Jan 5, 2015 | clinicaltrials |
| NCT00220285 | Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 45 | BayerINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
| NCT00661180 | Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec(ORACLE) | completed | Phase 2 | 10 | BayerINDUSTRY | 2 | Dec 23, 2014 | clinicaltrials |
| NCT00079755 | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma | completed | Phase 2 | 80 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00283101 | A Safety Study in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 12 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00666484 | Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma | completed | Phase 2 | 47 | University College, LondonOTHER | 1 | Dec 4, 2014 | clinicaltrials |
| NCT00971763 | Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 62 | University College, LondonOTHER | 1 | Dec 4, 2014 | clinicaltrials |
| NCT00660231 | Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma(GemBex) | completed | Phase 2 | 36 | University College, LondonOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00858806 | Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy(INTERIM0407) | completed | Phase 2 | 78 | Università degli Studi di BresciaOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT01998893 | A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma | completed | Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00039377 | Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Nov 24, 2014 | clinicaltrials |
| NCT00833560 | A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy | completed | Phase 2 | 401 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Nov 21, 2014 | clinicaltrials |
| NCT00911859 | A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 118 | Janssen Research & Development, LLCINDUSTRY | 11 | Nov 18, 2014 | clinicaltrials |
| NCT01470456 | Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 50 | SanofiINDUSTRY | 3 | Nov 13, 2014 | clinicaltrials |
| NCT00513955 | Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 50 | University Hospital Plymouth NHS TrustOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00891839 | Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma | completed | Phase 2 | 45 | CephalonINDUSTRY | 2 | Nov 4, 2014 | clinicaltrials |
| NCT01068392 | Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL) | completed | Phase 2 | 42 | Dong-A University HospitalOTHER | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00433537 | Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00388193 | Rituximab Combined With Chemotherapy in Burkitt's Lymphoma | completed | Phase 2 | 20 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT00564200 | MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning(MINIALO-VELCAD) | completed | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT00869999 | Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | completed | Phase 2 | 26 | Massachusetts General HospitalOTHER | 1 | Oct 27, 2014 | clinicaltrials |
| NCT01926639 | Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma(Lymvac-1) | completed | Phase 2 | 14 | Oslo University HospitalOTHER | 1 | Oct 23, 2014 | clinicaltrials |
| NCT00795756 | Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 145 | Northern Italy Leukemia GroupOTHER | 1 | Oct 22, 2014 | clinicaltrials |
| NCT00505895 | FM 140 vs FM100 Study in Patients With Multiple Myeloma | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT00602771 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00430066 | Effects of Imatinib Mesylate in Polycythemia Vera | completed | Phase 2 | 9 | Niguarda HospitalOTHER | 0 | Oct 8, 2014 | clinicaltrials |
| NCT00230282 | Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia | completed | Phase 2 | 25 | Steven E. CoutreOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00109928 | S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 34 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 1, 2014 | clinicaltrials |
| NCT00357500 | Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | completed | Phase 2 | 101 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2014 | clinicaltrials |
| NCT01502982 | Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)(CRY-04) | completed | Phase 2 | 160 | Nordic Lymphoma GroupNETWORK | 4 | Sep 30, 2014 | clinicaltrials |
| NCT00546897 | Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Sep 29, 2014 | clinicaltrials |
| NCT01095757 | Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection | completed | Phase 2 | 45 | Emory UniversityOTHER | 1 | Sep 29, 2014 | clinicaltrials |
| NCT00057811 | Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | completed | Phase 2 | 97 | Children's Oncology GroupNETWORK | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00074737 | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | completed | Phase 2 | 53 | Eleos, Inc.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
| NCT01290120 | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma | completed | Phase 2 | 182 | Northern Italy Leukemia GroupOTHER | 1 | Sep 16, 2014 | clinicaltrials |
| NCT00189488 | Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | completed | Phase 2 | 155 | Swedish Orphan BiovitrumINDUSTRY | 0 | Sep 15, 2014 | clinicaltrials |
| NCT00225212 | Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 35 | Stanford UniversityOTHER | 1 | Sep 15, 2014 | clinicaltrials |
| NCT00532259 | CT-011 MAb in DLBCL Patients Following ASCT | completed | Phase 2 | 72 | CureTech LtdINDUSTRY | 3 | Sep 12, 2014 | clinicaltrials |
Data updated 24 days agoSource updated Feb 18, 2015source: clinicaltrials